Blood · 2018 · 116 citations · 53 references
MedicineMolecular BiologyOncologyCancer ImmunologyMolecular OncologyTumor ImmunologyAntigen Receptor Gene RearrangementLymphoid NeoplasmsLymphoid TumorsTumor AntigensTumor BiologyTumor ImmunopathologyLymphoma HistopathologyLymphoma MicroenvironmentLymphoma Molecular ClassificationLymphoma PathogenesisNeoplastic Lymphoid DifferentiationTumor Immunogenomics
rearrangements define a molecularly distinct subgroup of ALCLs, and that immunogenic cues related to antigenicity, costimulatory molecule expression, and inactivity of the PD-1/PD-L1 immune checkpoint likely contribute to their favorable prognosis. More aggressive ALCLs might be pharmacologically reprogrammed to a DUSP22-like immunogenic molecular signature through the use of demethylating agents and/or immune checkpoint inhibitors.
53
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello et al. · New England Journal of Medicine · 2014 · 3.5K citations · Full text
Medicine, Oncology, Pharmacology +17
Kerry J. Savage, Nancy L. Harris, Julie M. Vose et al. · Blood · 2008 · 854 citations · Full text
Marcel W. Bekkenk, Françoise A. M. J. Geelen, Pieter C. van Voorst Vader et al. · Blood · 2000 · 782 citations
Medicine, Dermatology, Pathology +16